Zynex, Inc. (NASDAQ:ZYXI) is set to announce second quarter earning results on Tuesday 28th July 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, ZYXI to report 2Q20 income of $ 0.09 per share.
For the full year, analysts anticipate top line of $ 83.50 million, while looking forward to income of $ 0.34 per share bottom line.
The Company Outlook
Revenue for 2Q20 are expected in a range of $ 17.50 million ~ $ 18.00 million
Full Year 2020 topline are forecasted in a range of$ 78.00 million ~ $ 83.00 million
Click Here For More Historical Outlooks Of Zynex, Inc.
Previous Quarter Performance
Zynex, Inc. communicated income for the first quarter of $ 0.09 per share, from the revenue of $ 15.23 million. Wall street analysts are predicting, ZYXI to report 1Q20 income of $ 0.06 per share from revenue of $ 14.57 million. The bottom line results beat street analysts by $ 0.03 or 50.00 percent, at the same time, top line results outshined analysts by $ 0.66 million or 4.53 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Zynex, Inc.
Stock Performance
According to the previous trading day, closing price of ZYXI was $ 19.51, representing a 159.79 % increase from the 52 week low of $ 7.51 and a 34.38 % decrease over the 52 week high of $ 29.73.
The company has a market capital of $ 677.87 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”ZYXI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 13th July 2020, downgraded by B. Riley to Neutral from Buy rating.
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also distributes electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support.
